Cite
HARVARD Citation
Schiff, M. et al. (2006). Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Annals of the rheumatic diseases. 65 (7), pp. 889-894. [Online].